Lord Abbett & CO. LLC Has $16.09 Million Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Lord Abbett & CO. LLC increased its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 6.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 730,339 shares of the company's stock after buying an additional 46,119 shares during the period. Lord Abbett & CO. LLC owned 0.35% of Cellebrite DI worth $16,089,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. State Street Corp lifted its holdings in Cellebrite DI by 7.3% during the 3rd quarter. State Street Corp now owns 443,700 shares of the company's stock worth $7,472,000 after buying an additional 30,052 shares in the last quarter. Barclays PLC grew its position in shares of Cellebrite DI by 29.1% during the 3rd quarter. Barclays PLC now owns 263,657 shares of the company's stock worth $4,439,000 after buying an additional 59,395 shares during the period. Tidal Investments LLC lifted its holdings in Cellebrite DI by 59.3% in the third quarter. Tidal Investments LLC now owns 104,478 shares of the company's stock valued at $1,759,000 after buying an additional 38,887 shares during the period. Principal Financial Group Inc. bought a new position in Cellebrite DI in the third quarter valued at approximately $23,402,000. Finally, JPMorgan Chase & Co. raised its position in shares of Cellebrite DI by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 427,655 shares of the company's stock valued at $7,202,000 after acquiring an additional 75,092 shares during the last quarter. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Trading Up 2.1 %

NASDAQ CLBT traded up $0.41 on Friday, hitting $20.27. 319,508 shares of the company's stock were exchanged, compared to its average volume of 1,411,585. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30. The stock has a 50-day moving average of $18.79 and a 200-day moving average of $20.16. The stock has a market cap of $4.85 billion, a price-to-earnings ratio of -14.57, a P/E/G ratio of 4.27 and a beta of 1.44.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CLBT. Lake Street Capital boosted their target price on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Finally, JPMorgan Chase & Co. increased their price target on Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $23.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.